Patients with Chronic Liver Disease

• PO (Adults ): Platelet count <40 × 10⁹/L: 60 mg once daily for 5 days (should be initiated 10–13 days prior to scheduled procedure; procedure should be performed 5–8 days after last dose); Platelet count 40–<50 × 10⁹/L: 40 mg once daily for 5 days (should be initiated 10–13 days prior to scheduled procedure; procedure should be performed 5–8 days after last dose.

Patients with Chronic Immune Thrombocytopenia

• PO (Adults ): Dose levels recommended for titration of therapy based on platelet counts: Dose Level 1: 20 mg once weekly; Dose Level 2: 20 mg twice weekly OR 40 mg once weekly; Dose Level 3: 20 mg 3 times weekly; Dose Level 4: 20 mg once daily; Dose Level 5: 40 mg 3 times weekly AND20 mg the remaining 4 days of the wk; Dose Level 6: 40 mg once daily; initiate therapy at Dose Level 4 (20 mg once daily); if platelet count <50 × 10⁹/L after 2 wk of therapy, ↑ one Dose Level; if platelet count 50–200 × 10⁹/L after 2 wk of therapy, continue current Dose Level; if platelet count 200–400 × 10⁹/L after 2 wk of therapy, ↓ one Dose Level; if platelet count >400 × 10⁹/L, discontinue avatrombopag and restart therapy (↓ one Dose Level) once platelet count <150 × 10⁹/L. Concurrent use of moderate or strong dual inhibitors of CYP3A4 and CYP2C9: Initiate therapy at Dose Level 3 (20 mg 3 times weekly). Concurrent use of moderate or strong dual inducers of CYP3A4 and CYP2C9: Initiate therapy at Dose Level 6 (40 mg once daily).